유전자 편집 시장 규모, 점유율, 동향 분석 보고서 : 제품 및 서비스별, 기술별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)

Gene Editing Market Summary

The global gene editing market size was estimated at USD 5.87 billion in 2025 and is projected to reach USD 18.55 billion by 2033, growing at a CAGR of 15.71% from 2026 to 2033. This growth is supported by rising adoption of advanced gene therapies, increasing investments in biopharmaceutical research, and growing demand for precision medicine.

Growing demand for curative genetic therapies

The increasing need for precision medicine in rare and genetic disorders is one of the main factors driving the gene editing market, as health care systems are increasingly inclined to shift from symptomatic management to more targeted, root-cause interventions. Many rare diseases are monogenic, making them appropriate candidates for gene-editing techniques that can directly fix, silence, or alter the defective genes. The customary chronic treatment approaches often entail lifelong prescription of medicines with limited effect. However, gene editing opens the door to either single or very rare interventions with lasting results.

The developers need much more than basic editing tools. They need to perform mutation-specific programs with advanced editing enzymes, guide RNA design, delivery optimization, and robust analytical validation. As a result, there has been a continuous demand for gene-editing reagents, GMP-grade components, and specialized contract research and manufacturing services. The combination of the above factors, namely unmet clinical need, precision-focused healthcare strategies, and scalable platform development, has made gene editing a critical growth engine in the next generation of therapeutic innovations.

Global Gene Editing Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global gene editing market report based on product & service, technology, end-user, and region:

• Product & Service Outlook (Revenue, USD Billion, 2021 - 2033)
• Reagents and Consumables
• Software and Systems
• Services
• Technology Outlook (Revenue, USD Billion, 2021 - 2033)
• CRISPR-Cas System
• Transcription Activator-Like Effector Nucleases (TALENs)
• Zinc Finger Nucleases (ZFNs)
• Meganucleases/Homing Endonucleases
• End-user Outlook (Revenue, USD Billion, 2021 - 2033)
• Biotechnology and Pharmaceutical Companies
• University and Research Institutes
• Other End-users
• Regional Outlook (Revenue, USD Billion, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product & Service
  • 1.2.2. Technology
  • 1.2.3. End User
• 1.3. Research Methodology
• 1.4. Information Procurement
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Gene Editing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Growing Demand For Curative Genetic Therapies
    • 3.2.1.2. Expansion Of Enabling Ecosystem
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Capital-Intensive Development Pathways
    • 3.2.2.2. Fragmented Regulatory Landscape
  • 3.2.3. Market Opportunity Analysis
    • 3.2.3.1. Monetization Beyond Therapeutic Products
    • 3.2.3.2. Broadening Application Spectrum
  • 3.2.4. Market Challenge Analysis
    • 3.2.4.1. Limitations In Targeted In Vivo Delivery
    • 3.2.4.2. Complex Intellectual Property Environment
  • 3.2.5. Key Partnerships & Collaborations
  • 3.2.6. Patent Analysis
  • 3.2.7. Funding & Investment Landscape
• 3.3. Industry Analysis Tools
  • 3.3.1. SWOT Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. Porter's Analysis

Chapter 4. Gene Editing Market: Product & Service Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Product & Service Market Share, 2025 & 2033
• 4.3. Reagents and Consumables
  • 4.3.1. Reagents and Consumables Market Estimates and Forecasts 2021 to 2033 (USD million)
• 4.4. Software and Systems
  • 4.4.1. Software and Systems Market Estimates and Forecasts 2021 to 2033 (USD million)
• 4.5. Services
  • 4.5.1. Services Market Estimates and Forecasts 2021 to 2033 (USD million)

Chapter 5. Gene Editing Market: Technology Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Technology Market Share, 2025 & 2033
• 5.3. CRISPR-Cas System
  • 5.3.1. CRISPR-Cas System Market Estimates and Forecasts 2021 to 2033 (USD million)
• 5.4. Transcription Activator-Like Effector Nucleases (TALENs)
  • 5.4.1. Transcription Activator-Like Effector Nucleases (TALENs) Market Estimates and Forecasts 2021 to 2033 (USD million)
• 5.5. Zinc Finger Nucleases (ZFNs)
  • 5.5.1. Zinc Finger Nucleases (ZFNs) Market Estimates and Forecasts 2021 to 2033 (USD million)
• 5.6. Meganucleases/Homing Endonucleases
  • 5.6.1. Meganucleases/Homing Endonucleases Market Estimates and Forecasts 2021 to 2033 (USD million)
• 5.7. Technology Landscape and Competitive Insights

Chapter 6. Gene Editing Market: End User Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. End User Market Share, 2025 & 2033
• 6.3. Biotechnology and Pharmaceutical Companies
  • 6.3.1. Biotechnology and Pharmaceutical Companies Market Estimates and Forecasts 2021 to 2033 (USD million)
• 6.4. University and Research Institutes
  • 6.4.1. University and Research Institutes Market Estimates and Forecasts 2021 to 2033 (USD million)
• 6.5. Other End Users
  • 6.5.1. Other End Users Market Estimates and Forecasts 2021 to 2033 (USD million)

Chapter 7. Gene Editing Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Dashboard
• 7.2. Regional Market Share Analysis, 2025 & 2033
• 7.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 7.4. North America
  • 7.4.1. U.S.
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework
    • 7.4.1.3. Reimbursement environment
    • 7.4.1.4. Growth drivers
    • 7.4.1.5. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.2. Canada
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework
    • 7.4.2.3. Reimbursement environment
    • 7.4.2.4. Growth drivers
    • 7.4.2.5. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.3. Mexico
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework
    • 7.4.3.3. Reimbursement environment
    • 7.4.3.4. Growth drivers
    • 7.4.3.5. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 7.5. Europe
  • 7.5.1. UK
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework
    • 7.5.1.3. Reimbursement environment
    • 7.5.1.4. Growth drivers
    • 7.5.1.5. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.2. Germany
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework
    • 7.5.2.3. Reimbursement environment
    • 7.5.2.4. Growth drivers
    • 7.5.2.5. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.3. France
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework
    • 7.5.3.3. Reimbursement environment
    • 7.5.3.4. Growth drivers
    • 7.5.3.5. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.4. Italy
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework
    • 7.5.4.3. Reimbursement environment
    • 7.5.4.4. Growth drivers
    • 7.5.4.5. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.5. Spain
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework
    • 7.5.5.3. Reimbursement environment
    • 7.5.5.4. Growth drivers
    • 7.5.5.5. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.6. Norway
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework
    • 7.5.6.3. Reimbursement environment
    • 7.5.6.4. Growth drivers
    • 7.5.6.5. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.7. Sweden
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Regulatory framework
    • 7.5.7.3. Reimbursement environment
    • 7.5.7.4. Growth drivers
    • 7.5.7.5. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.8. Denmark
    • 7.5.8.1. Key country dynamics
    • 7.5.8.2. Regulatory framework
    • 7.5.8.3. Reimbursement environment
    • 7.5.8.4. Growth drivers
    • 7.5.8.5. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Japan
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework
    • 7.6.1.3. Reimbursement environment
    • 7.6.1.4. Growth drivers
    • 7.6.1.5. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.2. China
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework
    • 7.6.2.3. Reimbursement environment
    • 7.6.2.4. Growth drivers
    • 7.6.2.5. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.3. India
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework
    • 7.6.3.3. Reimbursement environment
    • 7.6.3.4. Growth drivers
    • 7.6.3.5. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.4. Australia
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework
    • 7.6.4.3. Reimbursement environment
    • 7.6.4.4. Growth drivers
    • 7.6.4.5. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.5. South Korea
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework
    • 7.6.5.3. Reimbursement environment
    • 7.6.5.4. Growth drivers
    • 7.6.5.5. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.6. Thailand
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework
    • 7.6.6.3. Reimbursement environment
    • 7.6.6.4. Growth drivers
    • 7.6.6.5. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 7.7. Latin America
  • 7.7.1. Brazil
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework
    • 7.7.1.3. Reimbursement environment
    • 7.7.1.4. Growth drivers
    • 7.7.1.5. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.2. Argentina
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework
    • 7.7.2.3. Reimbursement environment
    • 7.7.2.4. Growth drivers
    • 7.7.2.5. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 7.8. MEA
  • 7.8.1. South Africa
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Regulatory framework
    • 7.8.1.3. Reimbursement environment
    • 7.8.1.4. Growth drivers
    • 7.8.1.5. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8.2. Saudi Arabia
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework
    • 7.8.2.3. Reimbursement environment
    • 7.8.2.4. Growth drivers
    • 7.8.2.5. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8.3. UAE
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. Regulatory framework
    • 7.8.3.3. Reimbursement environment
    • 7.8.3.4. Growth drivers
    • 7.8.3.5. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8.4. Kuwait
    • 7.8.4.1. Key country dynamics
    • 7.8.4.2. Regulatory framework
    • 7.8.4.3. Reimbursement environment
    • 7.8.4.4. Growth drivers
    • 7.8.4.5. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Global Competitive Landscape

• 8.1. Global Market Position Analysis, 2025

Chapter 9. North America Competitive Landscape

• 9.1. Company Profiles
  • 9.1.1. Thermo Fisher Scientific Inc.
    • 9.1.1.1. Company overview
    • 9.1.1.2. Financial performance
    • 9.1.1.3. Product benchmarking
    • 9.1.1.4. Strategic initiatives
  • 9.1.2. Revvity
    • 9.1.2.1. Company overview
    • 9.1.2.2. Financial performance
    • 9.1.2.3. Product benchmarking
    • 9.1.2.4. Strategic initiatives
  • 9.1.3. Danaher
    • 9.1.3.1. Company overview
    • 9.1.3.2. Financial performance
    • 9.1.3.3. Product benchmarking
    • 9.1.3.4. Strategic initiatives
  • 9.1.4. Intellia Therapeutics
    • 9.1.4.1. Company overview
    • 9.1.4.2. Financial performance
    • 9.1.4.3. Product benchmarking
    • 9.1.4.4. Strategic initiatives
  • 9.1.5. Sangamo Therapeutics
    • 9.1.5.1. Company overview
    • 9.1.5.2. Financial performance
    • 9.1.5.3. Product benchmarking
    • 9.1.5.4. Strategic initiatives
  • 9.1.6. Beam Therapeutics
    • 9.1.6.1. Company overview
    • 9.1.6.2. Financial performance
    • 9.1.6.3. Product benchmarking
    • 9.1.6.4. Strategic initiatives
  • 9.1.7. Illumina, Inc.
    • 9.1.7.1. Company overview
    • 9.1.7.2. Financial performance
    • 9.1.7.3. Product benchmarking
    • 9.1.7.4. Strategic initiatives
  • 9.1.8. Editas Medicine
    • 9.1.8.1. Company overview
    • 9.1.8.2. Financial performance
    • 9.1.8.3. Product benchmarking
    • 9.1.8.4. Strategic initiatives
  • 9.1.9. Synthego
    • 9.1.9.1. Company overview
    • 9.1.9.2. Financial performance
    • 9.1.9.3. Product benchmarking
    • 9.1.9.4. Strategic initiatives

Chapter 10. Europe Competitive Landscape

• 10.1. Company Profiles
  • 10.1.1. Merck KGaA
    • 10.1.1.1. Company overview
    • 10.1.1.2. Financial performance
    • 10.1.1.3. Product benchmarking
    • 10.1.1.4. Strategic initiatives
  • 10.1.2. QIAGEN
    • 10.1.2.1. Company overview
    • 10.1.2.2. Financial performance
    • 10.1.2.3. Product benchmarking
    • 10.1.2.4. Strategic initiatives
  • 10.1.3. Cellectis S.A.
    • 10.1.3.1. Company overview
    • 10.1.3.2. Financial performance
    • 10.1.3.3. Product benchmarking
    • 10.1.3.4. Strategic initiatives
  • 10.1.4. CRISPR Therapeutics
    • 10.1.4.1. Company overview
    • 10.1.4.2. Financial performance
    • 10.1.4.3. Product benchmarking
    • 10.1.4.4. Strategic initiatives
  • 10.1.5. Vivlion GmbH
    • 10.1.5.1. Company overview
    • 10.1.5.2. Financial performance
    • 10.1.5.3. Product benchmarking
    • 10.1.5.4. Strategic initiatives
  • 10.1.6. Eurofins Genomics
    • 10.1.6.1. Company overview
    • 10.1.6.2. Financial performance
    • 10.1.6.3. Product benchmarking
    • 10.1.6.4. Strategic initiatives
  • 10.1.7. AMSBIO
    • 10.1.7.1. Company overview
    • 10.1.7.2. Financial performance
    • 10.1.7.3. Product benchmarking
    • 10.1.7.4. Strategic initiatives
  • 10.1.8. OZ Biosciences
    • 10.1.8.1. Company overview
    • 10.1.8.2. Financial performance
    • 10.1.8.3. Product benchmarking
    • 10.1.8.4. Strategic initiatives

Chapter 11. Asia Pacific Competitive Landscape

• 11.1. Company Profiles
  • 11.1.1. GenScript
    • 11.1.1.1. Company overview
    • 11.1.1.2. Financial performance
    • 11.1.1.3. Product benchmarking
    • 11.1.1.4. Strategic initiatives
  • 11.1.2. Takara Bio
    • 11.1.2.1. Company overview
    • 11.1.2.2. Financial performance
    • 11.1.2.3. Product benchmarking
    • 11.1.2.4. Strategic initiatives
  • 11.1.3. Macrogen, Inc.
    • 11.1.3.1. Company overview
    • 11.1.3.2. Financial performance
    • 11.1.3.3. Product benchmarking
    • 11.1.3.4. Strategic initiatives
  • 11.1.4. BRL MEDICINE
    • 11.1.4.1. Company overview
    • 11.1.4.2. Financial performance
    • 11.1.4.3. Product benchmarking
    • 11.1.4.4. Strategic initiatives
  • 11.1.5. Biocytogen
    • 11.1.5.1. Company overview
    • 11.1.5.2. Financial performance
    • 11.1.5.3. Product benchmarking
    • 11.1.5.4. Strategic initiatives
  • 11.1.6. BGI Genomics
    • 11.1.6.1. Company overview
    • 11.1.6.2. Financial performance
    • 11.1.6.3. Product benchmarking
    • 11.1.6.4. Strategic initiatives
  • 11.1.7. Bioneer
    • 11.1.7.1. Company overview
    • 11.1.7.2. Financial performance
    • 11.1.7.3. Product benchmarking
    • 11.1.7.4. Strategic initiatives